KnE Life Sciences

ISSN: 2413-0877

The latest conference proceedings on life sciences, medicine and pharmacology.

CCR5Δ32 POLYMORPHISM NOT DETECTED IN HIV PATIENTS IN VOLUNTARY COUNSELING AND TESTING MOEWARDI GENERAL HOSPITAL SURAKARTA, INDONESIA

Published date: Sep 20 2015

Journal Title: KnE Life Sciences

Issue title: International Conference on Biological Sciences (ICBS-2013)

Pages: 481-483

DOI: 10.18502/kls.v2i1.196

Authors:

Yulia Sari

Sri Haryati

Dhani Redhono

Afiono Agung Prasetyo - afie.agp.la@gmail.com

Abstract:

Background: The CCR5.32 polymorphism (a naturally occurring 32-bp deletion in CCR5) influences the ability of HIV-1 to infect the target cells. Homozygosity for CCR5.32 prevents infection of HIV-1 R5 strain, while the heterozygous is associated with lower plasma viral load and delayed progression to acquired immune deficiency syndrome (AIDS). However, there is no report about the presentation of CCR5.32 polymorphisms in Indonesian HIV patients. The aim of this study is to detect CCR5.32 polymorphisms in Indonesian HIV patients, especially in Voluntary Counseling and Testing Moewardi General Hospital Surakarta, Indonesia. In an ongoing molecular epidemiology study of blood borne virus, 154 HIV patients in Moewardi General Hospital Surakarta were used for the study. The blood samples were collected during November – December 2011. The blood samples were aliquoted and fractionated. The DNA was extracted from all blood samples, and subjected for the PCR assay to detect the presentation of CCR5.32 polymorphisms. Internal amplification control was included in all assays. PCR products were analyzed in 3% agarose. The results showed that CCR5.32 polymorphism was not detected in all blood samples. So it can be concluded that all patients in this study had the CCR5 wild type.


Keywords: CCR5.32, HIV, Indonesia.

References:

Didigu, C.A., and R.W. Doms. 2012. Novel approaches to inhibit HIV entry. Viruses, vol. 4:309-324.
Grivel, J.C., R.J. Shattock, and L.B. Margolis. 2011. Selective transmission of R5 HIV-1 variants: Where is the gatekeeper? J Transl Med, vol. 9 Suppl 1:S6.
Gupta, A., and H. Padh. 2012. The global distribution of CCR5 delta 32 polymorphism: role in HIV-1 protection. BMC Infect Dis, vol. 12 (Suppl 1):O16.
Huang, Y., W.A. Paxton, S.M. Wolinsky, A.U. Neumann, L. Zhang, T. He, S. Kang, D. Ceradini, Z. Jin, K. Yazdanbakhsh, K. Kunstman, D. Erickson, E. Dragon, N.R. Landau, J. Phair, D.D. Ho, and R.A. Koup. 1996. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med, vol. 2:1240-1243.
Hyde, C.L., A. Macinnes, F.A. Sanders, J.F. Thompson, R.A. Mazzarella, O. Faergeman, D.F. van Wijk, L. Wood, M. Lira, and S.A. Paciga. 2010. Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients. Circ Cardiovasc Genet, vol. 3:162-168.
Liu, S., C. Kong, J. Wu, H. Ying, and H. Zhu. 2012. Effect of CCR5-D32 heterozygosity on HIV-1 susceptibility: A meta-analysis. PLoS ONE, vol. 7: e35020.

Download
HTML
Cite
Share
statistics

180 Abstract Views

188 PDF Downloads